Bayer Presents FIDELIO-DKD Phase III Study Cardiovascular Subgroup Analysis of Patients With Chronic Kidney Disease and Type 2 Diabetes Late-breaking data presented at AHA 2020 Scientific Sessions and ...
Bayer announced today late-breaking data from a pre-specified exploratory subgroup analysis of the FIDELIO-DKD Phase III study, in which the investigational drug finerenone, compared to placebo, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results